TRIPLE NEGATIVE BREAST CANCER

This study tested an experimental drug called BT-001, injected directly into tumors, either alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (like melanoma, lung, or breast cancer). The goal was to see if it was safe and could shrink tumors. The…

This early-phase study tested a new drug called FAZ053, which helps the immune system fight cancer, given alone or with another drug (PDR001) in 154 adults with advanced solid tumors (including triple-negative breast cancer and rare sarcomas). The main goal was to check safety an…

This study tested a new drug called azenosertib combined with two standard cancer drugs (carboplatin and pembrolizumab) in people with metastatic triple-negative breast cancer. The goal was to find the safest dose and see if the combination could shrink tumors. Only 7 people took…

This study tested a new drug called OC-001, either by itself or combined with avelumab (an immunotherapy), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The trial was stopped early, and only 73 people were e…

This study tested a new drug called NUV-868, alone or with other cancer drugs (olaparib or enzalutamide), in 82 adults with advanced solid tumors like ovarian, pancreatic, prostate, or breast cancer. The main goals were to check safety and find the right dose. The trial was stopp…

This study tested whether giving the immunotherapy drug atezolizumab alone for two weeks before starting chemotherapy could improve outcomes for people with triple-negative breast cancer. The trial enrolled 442 participants and compared this approach to starting atezolizumab and …

This early-stage study tested an experimental oral drug called NKT3447 in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in people with advanced solid tumors like breast, kidney, ovarian, head and neck, colorectal, lung cancer, or melanoma. The goal was to check safety and see if tumors shrank. The st…

This study tested an experimental drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors. However, the study…

This study tested a combination of chemotherapy, an immunotherapy drug (pembrolizumab), and gene therapy (IL-12) in 8 women with a tough-to-treat type of breast cancer (triple negative) that had stopped responding to standard treatment. The goal was to see if the combination coul…

This early-phase study tested a new drug called SO-C101, alone or with pembrolizumab, in 115 people with advanced solid tumors (like lung, kidney, or skin cancer) that stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study …

This study tested a combination of two drugs, ZEN003694 and talazoparib, in people with triple-negative breast cancer who do not have BRCA gene mutations. The goal was to see if the combo could shrink tumors or slow the disease. The trial was stopped early, so results are limited…

This study tested whether combining two drugs—vidutolimod (injected into tumors) and cemiplimab (given through a vein)—could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, lung cancer, and throat cancer. The trial enrolled 77 adults and…

This study tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The goal was to check safety and see if the drug could shrink tumors. The trial was stopped early, so results are limited.

This study tested a drug called magrolimab combined with chemotherapy for people with advanced triple-negative breast cancer that cannot be removed by surgery. The goal was to see if the combination was safe and worked better than chemotherapy alone. The trial was stopped early, …